Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Transition Therapeutics Company Profile (NASDAQ:TTHI)

Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.24 (28.90% upside)

Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/15/2014HC WainwrightInitiated CoverageBuy$10.00ViewTweet This Rating  Share This Rating on StockTwits
4/29/2014RBC CapitalUpgradeUnderperform -> Sector Perform$5.50ViewTweet This Rating  Share This Rating on StockTwits
12/10/2013Canaccord GenuityUpgradeHold -> Buy$4.53 -> $9.21ViewTweet This Rating  Share This Rating on StockTwits
11/13/2013Canaccord GenuityBoost Price TargetHoldC$3.75 -> C$4.75ViewTweet This Rating  Share This Rating on StockTwits
6/17/2013Canaccord GenuityBoost Price TargetHoldC$3.25 -> C$3.75ViewTweet This Rating  Share This Rating on StockTwits
5/1/2013Canaccord GenuityBoost Price TargetC$2.30 -> C$3.25ViewTweet This Rating  Share This Rating on StockTwits
2/12/2013Byron CapitalUpgradeHold -> BuyViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2012 forward)